259 related articles for article (PubMed ID: 28325750)
1. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
MacGregor HL; Ohashi PS
Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
3. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
4. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
[TBL] [Abstract][Full Text] [Related]
5. Could B7-H4 serve as a target to activate anti-cancer immunity?
Wang L; Heng X; Lu Y; Cai Z; Yi Q; Che F
Int Immunopharmacol; 2016 Sep; 38():97-103. PubMed ID: 27258187
[TBL] [Abstract][Full Text] [Related]
6. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
7. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
[TBL] [Abstract][Full Text] [Related]
8. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.
Sica GL; Choi IH; Zhu G; Tamada K; Wang SD; Tamura H; Chapoval AI; Flies DB; Bajorath J; Chen L
Immunity; 2003 Jun; 18(6):849-61. PubMed ID: 12818165
[TBL] [Abstract][Full Text] [Related]
9. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
10. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
[TBL] [Abstract][Full Text] [Related]
11. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.
Smith JB; Stashwick C; Powell DJ
Gynecol Oncol; 2014 Jul; 134(1):181-189. PubMed ID: 24657487
[TBL] [Abstract][Full Text] [Related]
12. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
13. Expression of co-stimulatory molecule B7-H4 in patients suffering from rheumatoid arthritis.
Chen L; Lu Y; Wang F; Zhou M; Chu Y; Ding W; Liu C; Xie J; Wu C; Jiang J
Immunol Lett; 2013; 154(1-2):25-30. PubMed ID: 23973734
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
[TBL] [Abstract][Full Text] [Related]
15. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
16. B7-H4, a promising target for immunotherapy.
Wang JY; Wang WP
Cell Immunol; 2020 Jan; 347():104008. PubMed ID: 31733822
[TBL] [Abstract][Full Text] [Related]
17. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
Yao Y; Ye H; Qi Z; Mo L; Yue Q; Baral A; Hoon DSB; Vera JC; Heiss JD; Chen CC; Zhang J; Jin K; Wang Y; Zang X; Mao Y; Zhou L
Clin Cancer Res; 2016 Jun; 22(11):2778-2790. PubMed ID: 27001312
[TBL] [Abstract][Full Text] [Related]
18. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation.
Wang X; Hao J; Metzger DL; Ao Z; Chen L; Ou D; Verchere CB; Mui A; Warnock GL
PLoS One; 2012; 7(1):e28232. PubMed ID: 22238573
[TBL] [Abstract][Full Text] [Related]
20. Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.
Dangaj D; Scholler N
Methods Mol Biol; 2015; 1319():37-49. PubMed ID: 26060068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
